The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.
In patients with decreased resistance to infection, Staphylococcus aureus is a major cause of bacteremia and its complications. The capsular polysaccharides are essential for the pathogenesis of and immunity to S. aureus infection and are targets for vaccines. ⋯ In patients receiving hemodialysis, a conjugate vaccine can confer partial immunity against S. aureus bacteremia for approximately 40 weeks, after which protection wanes as antibody levels decrease.